Croissy-Beaubourg and Montpellier, September 5, 2016 – THERADIAG (ISIN: FR0004197747, Ticker: ALTER, PEA-PME eligible), a company specialized in in vitro diagnostics and theranostics, reports that, on August 29, Janssen Biotech Inc. announced the launch of a program to offer free monitoring tests to help healthcare professionals (HCP) better use Remicade® in treating patients with inflammatory bowel disease (IBD).
According to the terms of an agreement between Janssen Biotech and Miraca Life Sciences, the InformTxTM therapeutic drug monitoring tests will be provided within the framework of the Janssen2Inform program[1]. Based on the licensing agreement signed in November 2015[2] between Miraca Life Sciences and Theradiag, Theradiag supplies raw materials and has provided an exclusive “know-how” license to Miraca Life Sciences.
“We are delighted to be contributing to this unprecedented new program launched by Janssen Biotech, Inc. with Miraca Life Sciences. This initiative will help increase the use of drug monitoring tests by healthcare professionals in the United States”, comments Michel Finance, CEO of Theradiag. “Sales of raw material to Miraca Life Sciences and royalties on Miraca’ sales represent a substantial growth potential in the United States for Theradiag”.
With the help of the Janssen 2Inform program, therapeutic drug monitoring test results will help HCPs evaluate how a patient is responding to treatment with REMICADE® and, in turn, identify necessary dosing regimen adjustments to optimize the patient’s response.
The Janssen 2Inform program consists of giving healthcare professionals access to two free Remicade® monitoring tests per patient per year.
About Theradiag
Capitalizing on its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostics tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag notably markets the Lisa Tracker® range (CE marked), which is a comprehensive multiparameter theranostic solution for patients with autoimmune diseases treated with biotherapies. With its subsidiary Prestizia, Theradiag is developing new biomarkers based on microRNAs for the diagnosis and monitoring of rectal cancer, auto-immune and inflammatory diseases and HIV/AIDS. Theradiag is thus participating in the development of customized treatment, which favors the individualization of treatments, the evaluation of their efficacy and the prevention of drug resistance. The Company is based in Marne-la-Vallée, near Paris, and in Montpellier, and has over 75 employees.
For more information about Theradiag, please visit our website: www.theradiag.com
Theradiag Investor Relations Fabienne François CFO Tel.: +33 (0)1 64 62 10 12 | NewCap Financial Communications & Investor Relations Valentine Brouchot Tel.: +33 (0)1 44 71 94 94 | Alize RP Press Relations Caroline Carmagnol / Florence Portejoie Tel.: +33 (0)1 44 54 36 64 |
[1] See Janssen Biotech, Inc. press release of August 30, 2016: Janssen Biotech (JNJ) Launches First And Only Program To Offer Free Therapeutic Drug Monitoring To Help Healthcare Professionals Treat Patients Living With Inflammatory Bowel Diseases
[2] See press release of November 18, 2015: Theradiag announces strategic agreement with Miraca Life Sciences in the USA.